This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Congress may give the federal government power virtually to dictate copy for drug advertising, Pharmaceutical Manufacturers Association President Austin Smith told members of the Pharmaceutical Advertising Club in New York Sept. 20.
He said three proposed bills would stringently regulate the wording and display of medical journal advertising.
The Dingell bill, H.R. 6471, introduced in the House April 19, 1961, provides, he said, that "an advertisement of a prescription drug shall be deemed to be misleading in a material respect if such an advertisement fails to contain a conspicuous and truthful disclosure of (1) the quantitative formula of the drug with each active ingredient listed by its common or usual name, (2) the side effects of the drug, and (3) the contraindications of the drug."
A second bill, H.R. 11581, the socalled Administration bill introduced by Congressman Oren Harris May 3, 1962, goes further, providing in addition that ads must
Socialized Advertising. JAMA. 1962;182(2):35–37. doi:10.1001/jama.1962.03050410131045
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: